Table 2:
Treatment regimens after ICI therapy | n (%) |
---|---|
Platinum-based | 37 (47%) |
Pegylated liposomal doxorubicin (PLD) | 24 (30%) |
Gemcitabine | 18 (23%) |
Taxanes | 42 (53%) |
Topotecan/Irinotecan | 17 (22%) |
Hormones | 6 (8%) |
PARP | 10 (13%) |
Pemetrexed | 15 (19%) |
Other | 23 (29%) |
Bevacizumab after ICI therapy | |
Yes | 47 (59%) |
No | 32 (41%) |
ICI, immune checkpoint inhibitor; PARP, poly (ADP-ribose) polymerase